Scarica l'app Stockscreener
4.435
1.53%
-0.055
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Taysha Gene Therapies (TSHA) making progress on crucial Rett syndrome treatment - MSN
Taysha Gene Therapies (NASDAQ: TSHA) insider selling 200,000 shares - Stock Titan
Taysha Gene Therapies (TSHA) Price Target Increased by 12.72% to 9.96 - MSN
Aug Mood: Does Taysha Gene Therapies Inc have strong fundamentals2026 Buyback Activity & Expert Curated Trade Setups - baoquankhu1.vn
Aug Mood: Whats the fair value of Taysha Gene Therapies Inc stock2026 Spike Watch & Consistent Return Investment Signals - baoquankhu1.vn
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 earnings call transcript - MSN
Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome Treatment - Yahoo Finance
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 6.9% on Analyst Upgrade - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $17.00 - MarketBeat
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Canaccord raises Taysha Gene Therapies price target on trial progress By Investing.com - Investing.com South Africa
Canaccord raises Taysha Gene Therapies price target on trial progress - Investing.com
Capricorn Fund Managers Ltd Makes New Investment in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
5 Best Multibagger Penny Stocks to Invest In - Insider Monkey
Citizens Maintains Taysha Gene Therapies (TSHA) Market Outperform Recommendation - MSN
Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset - MSN
Aug Patterns: Is Taysha Gene Therapies Inc undervalued by DCF analysis2026 Institutional & Reliable Price Breakout Alerts - baoquankhu1.vn
TSHA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
SG Americas Securities LLC Acquires 748,525 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Hennion & Walsh Asset Management Inc. Invests $1.70 Million in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Should you avoid Taysha Gene Therapies Inc stock right nowProfit Target & Weekly Top Gainers Trade List - baoquankhu1.vn
Taysha outlines 2026 BLA submission path for TSHA-102 as pivotal trial enrollment advances - MSN
Buybacks Report: Is Taysha Gene Therapies Inc undervalued by DCF analysisQuarterly Investment Review & AI Driven Stock Movement Reports - baoquankhu1.vn
Aug Catalysts: Will Taysha Gene Therapies Inc benefit from AI trendsJobs Report & Verified Momentum Stock Alerts - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Upgraded by Truist Financial - MarketBeat
Panic Selling: Whats the fair value of Taysha Gene Therapies Inc stockCEO Change & Technical Entry and Exit Alerts - baoquankhu1.vn
Levels Update: Whats the fair value of Taysha Gene Therapies Inc stock2026 Winners & Losers & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 8.5%Should You Buy? - MarketBeat
Cantor Fitzgerald reiterates Overweight on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.9%Time to Sell? - MarketBeat
Taysha Gene Therapies FY 2025 earnings preview - MSN
How FDA Breakthrough Status For TSHA-102 At Taysha Gene Therapies (TSHA) Has Changed Its Investment Story - Yahoo Finance
BMO Capital Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA) - The Globe and Mail
Taysha Gene Therapies Receives 'Moderate Buy' Rating from Analysts - National Today
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Chardan Capital Maintains Taysha Gene Therapies (TSHA) Buy Recommendation - MSN
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript - Insider Monkey
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $12.00 at Needham & Company LLC - MarketBeat
Decoding Taysha Gene Therapies Inc (TSHA): A Strategic SWOT Insi - GuruFocus
Taysha Gene Therapies Q4 Loss Of US$27.9m Tests Bullish TSHA 102 Narrative - simplywall.st
Taysha Gene Therapies Signals Momentum in Earnings Call - TipRanks
Taysha Gene Therapies (TSHA) Advances Rett Syndrome Treatment - GuruFocus
Jefferies raises Taysha Gene Therapies price target on trial progress By Investing.com - Investing.com Canada
Key facts: Taysha $109M loss; Q4 rev +171%; $320M cash; TSHA-102 safe, Q2'26 - TradingView
TSHA: Analyst Chardan Capital Maintains Buy Rating with $12 PT | - GuruFocus
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):